Esther Bommer

Roche (Switzerland) — Switzerland

Medicine · Health Sciences

7h-index510citations18works5.12yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(10), Cancer Immunotherapy and Biomarkers(8), Monoclonal and Polyclonal Antibodies Research(7), Immunotherapy and Immune Responses(4), HER2/EGFR in Cancer Research(2)

Publications18 total

CEA-4-1BBL: CEACAM5-Targeted 4-1BB Ligand Fusion Proteins for Cis Co-Stimulation with CEA-TCB
Antibodies·2025Open Access
863 A novel bispecific immuno-cytokine therapeutic: ‘switch on’ activity of a conditionally active PD1-IL2v delivering IL2v to PD1+ cells while reducing activity on PD1- cells
Regular and Young Investigator Award Abstracts·2025Open Access
CEA-4-1BBL: CEACAM5-Targeted 4-1BB Ligand Fusion Proteins for Cis Co-Stimulation with CEA-TCB
Preprints.org·2025Open Access
CEA-4-1BBL: Design and Optimization of a Novel CEACAM5-Targeted 4-1BB Ligand Antibody Fusion Protein to Provide Costimulation in Cis in Combination with T Cell Bispecific Antibodies
Preprints.org·2025Open Access
Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma
Blood·2025· 4 citedOpen Access
803 | POLATUZUMAB VEDOTIN AND GLOFITAMAB: A SYNERGISTIC APPROACH TO ANTI‐TUMOR ACTIVITY
Hematological Oncology·2025Open Access
CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy
Blood·2024· 32 citedOpen Access
RG6333 (CD19-CD28), a CD19-Targeted Affinity-Optimized CD28 Bispecific Antibody, Enhances and Prolongs the Anti-Tumor Activity of Glofitamab (CD20-TCB) in Preclinical Models
Blood·2022· 7 cited
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells
Nature·2022· 239 citedOpen Access
Differentiating PD-1+ stem-like CD8 T cells towards distinct effectors with enhanced therapeutic potential by an engineered IL-2 cis-targeted to PD-1
2021· 5 citedOpen Access
Corrigendum: Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity
Frontiers in Oncology·2021· 31 citedOpen Access
Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy
mAbs·2021· 111 citedOpen Access
Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity
Frontiers in Oncology·2020· 52 citedOpen Access
RG6076 (CD19-4-1BBL): CD19-Targeted 4-1BB Ligand Combination with Glofitamab As an Off-the-Shelf, Enhanced T-Cell Redirection Therapy for B-Cell Malignancies
Blood·2020· 8 cited
Abstract LB-389: Combination of TYRP1-TCB, a novel T cell bispecific antibody for the treatment of melanoma, with immunomodulatory agents
Cancer Research·2020· 7 cited
Abstract 1552: A novel PD1-IL2v immunocytokine for preferential <i>cis</i>-activation of IL-2R signaling on PD-1 expressing T cell subsets strongly potentiates anti-tumor T cell activity of PD-1 checkpoint inhibition and IL-2R-beta-gamma agonism
Cancer Research·2019· 6 cited
Abstract 1552: A novel PD1-IL2v immunocytokine for preferential<i>cis</i>-activation of IL-2R signaling on PD-1 expressing T cell subsets strongly potentiates anti-tumor T cell activity of PD-1 checkpoint inhibition and IL-2R-beta-gamma agonism
Immunology·2019
Premedication and Chemotherapy Agents do not Impair Imgatuzumab (GA201)-Mediated Antibody-Dependent Cellular Cytotoxicity and Combination Therapies Enhance Efficacy
Clinical Cancer Research·2015· 8 cited

Frequent Co-authors

Pablo Umaña(18), Marina Bacac(17), Christian Klein(17), Johannes Sam(15), Sara Colombetti(14), Valeria Nicolini(13), Sylvia Herter(8), Inja Waldhauer(7), Christina Claus(7), Maria Karagianni(6), Anne Freimoser–Grundschober(6), Marine Le Clech(6), Laura Codarri Deak(5), Stefanie Briner(5), Laura Lauener(4), Mario Perro(4), Leo Kunz(4), Ramona Schlenker(4), Marisa Mariani(4), Stefan Seeber(4)